LDXHF (Lumos Diagnostics Holdings) Current Deferred Taxes Liabilities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lumos Diagnostics Holdings Current Deferred Taxes Liabilities?

Lumos Diagnostics Holdings LDXHF -9.15% Current Deferred Taxes Liabilities is $0.00 Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Lumos Diagnostics Holdings's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Lumos Diagnostics Holdings Current Deferred Taxes Liabilities Related Terms

Lumos Diagnostics Holdings Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Current Deferred Taxes Liabilities Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Current Deferred Taxes Liabilities
0.00 0.00 0.00 0.00 0.00

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Lumos Diagnostics Holdings (LDXHF) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' Current Deferred Taxes Liabilities too high?
Lumos Diagnostics Holdings' current Current Deferred Taxes Liabilities is $0.00 Mil.
How does Lumos Diagnostics Holdings' Current Deferred Taxes Liabilities compare to ABT and SYK?
Lumos Diagnostics Holdings' Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Medical Devices & Instruments company?
A good Current Deferred Taxes Liabilities depends on the Medical Devices & Instruments industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (LDXHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.06 — trading 115% above its estimated fair value. The current Current Deferred Taxes Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Lumos Diagnostics Holdings (LDXHF), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDX:Australia
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.